Skip to main content

Market Overview

H.C. Wainwright Reiterates Buy On Second Sight Medical, Believes 'Significant' Growth Is Coming

Share:

In a report issued Wednesday, H.C. Wainwright analyst Amit Dayal reiterated a Buy rating and $21.00 price target on shares of Second Sight Medical Products Inc (NASDAQ: EYES).

The reiteration comes after the company announced the first implant and successful activation of the Argus II Retinal Prosthesis System in a dry age-related macular degeneration (AMD) patient. The implant was performed in a U.K. hospital, as a part of a feasibility study that is aimed at evaluating the safety and utility of the Argus II System. The firm believes four more patients will receive implants in the context of this study.

H.C. Wainwright conceives the event as a significant milestone for Second Sight, and likes to see the company it deliver in a timely fashion and meet its expectations. However, the analysts believe a larger study should be conducted now, to support market and regulatory approvals.

Regarding to the company’s retinitis pigmentosa (RP) trials and treatment, investors should note that "the Argus II System demonstrated a reasonable safety profile with no unexpected adverse events,” the note explains. If the company manages to obtain regulatory clearance for the AMD indication, its addressable market would enlarge substantially, from 375K patients (currently treated for RP), to roughly 2 million patients.

Overall, analysts at H.C. Wainwright believe Second Sight is poised for considerable growth going forward, especially as it is “protected by a substantial patent portfolio and market lead.” The firm is projecting a CAGR revenue growth of 50 percent till 2023, and thus thinks the company can easily grow into its high multiple.

Latest Ratings for EYES

DateFirmActionFromTo
Dec 2019Dougherty & Co.Initiates Coverage OnBuy
Mar 2016Rodman & RenshawMaintainsBuy
Jul 2015Rodman & RenshawInitiates Coverage OnBuy

View More Analyst Ratings for EYES
View the Latest Analyst Ratings

 

Related Articles (EYES)

View Comments and Join the Discussion!

Posted-In: Amit DayalAnalyst Color Biotech News Health Care Reiteration Analyst Ratings General

Latest Ratings

StockFirmActionPT
HR.UNCIBCMaintains17.0
FDGECIBCMaintains20.0
SNCCIBCMaintains40.0
APENLake StreetInitiates Coverage On12.0
PATHMacquarieInitiates Coverage On69.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com